Transfusion Volume for Children with Severe Anemia in Africa.
Anemia
/ complications
Blood Transfusion
/ economics
Child
Child, Preschool
Cost-Benefit Analysis
Female
Fever
/ complications
Follow-Up Studies
Health Care Costs
Hemoglobins
/ analysis
Humans
Infant
Length of Stay
/ economics
Malaria
/ complications
Malawi
/ epidemiology
Male
Patient Readmission
/ statistics & numerical data
Transfusion Reaction
/ epidemiology
Uganda
/ epidemiology
Journal
The New England journal of medicine
ISSN: 1533-4406
Titre abrégé: N Engl J Med
Pays: United States
ID NLM: 0255562
Informations de publication
Date de publication:
01 08 2019
01 08 2019
Historique:
entrez:
1
8
2019
pubmed:
1
8
2019
medline:
8
8
2019
Statut:
ppublish
Résumé
Severe anemia (hemoglobin level, <6 g per deciliter) is a leading cause of hospital admission and death in children in sub-Saharan Africa. The World Health Organization recommends transfusion of 20 ml of whole-blood equivalent per kilogram of body weight for anemia, regardless of hemoglobin level. In this factorial, open-label trial, we randomly assigned Ugandan and Malawian children 2 months to 12 years of age with a hemoglobin level of less than 6 g per deciliter and severity features (e.g., respiratory distress or reduced consciousness) to receive immediate blood transfusion with 20 ml per kilogram or 30 ml per kilogram. Three other randomized analyses investigated immediate as compared with no immediate transfusion, the administration of postdischarge micronutrients, and postdischarge prophylaxis with trimethoprim-sulfamethoxazole. The primary outcome was 28-day mortality. A total of 3196 eligible children (median age, 37 months; 2050 [64.1%] with malaria) were assigned to receive a transfusion of 30 ml per kilogram (1598 children) or 20 ml per kilogram (1598 children) and were followed for 180 days. A total of 1592 children (99.6%) in the higher-volume group and 1596 (99.9%) in the lower-volume group started transfusion (median, 1.2 hours after randomization). The mean (±SD) volume of total blood transfused per child was 475±385 ml and 353±348 ml, respectively; 197 children (12.3%) and 300 children (18.8%) in the respective groups received additional transfusions. Overall, 55 children (3.4%) in the higher-volume group and 72 (4.5%) in the lower-volume group died before 28 days (hazard ratio, 0.76; 95% confidence interval [CI], 0.54 to 1.08; P = 0.12 by log-rank test). This finding masked significant heterogeneity in 28-day mortality according to the presence or absence of fever (>37.5°C) at screening (P=0.001 after Sidak correction). Among the 1943 children (60.8%) without fever, mortality was lower with a transfusion volume of 30 ml per kilogram than with a volume of 20 ml per kilogram (hazard ratio, 0.43; 95% CI, 0.27 to 0.69). Among the 1253 children (39.2%) with fever, mortality was higher with 30 ml per kilogram than with 20 ml per kilogram (hazard ratio, 1.91; 95% CI, 1.04 to 3.49). There was no evidence of differences between the randomized groups in readmissions, serious adverse events, or hemoglobin recovery at 180 days. Overall mortality did not differ between the two transfusion strategies. (Funded by the Medical Research Council and Department for International Development, United Kingdom; TRACT Current Controlled Trials number, ISRCTN84086586.).
Sections du résumé
BACKGROUND
Severe anemia (hemoglobin level, <6 g per deciliter) is a leading cause of hospital admission and death in children in sub-Saharan Africa. The World Health Organization recommends transfusion of 20 ml of whole-blood equivalent per kilogram of body weight for anemia, regardless of hemoglobin level.
METHODS
In this factorial, open-label trial, we randomly assigned Ugandan and Malawian children 2 months to 12 years of age with a hemoglobin level of less than 6 g per deciliter and severity features (e.g., respiratory distress or reduced consciousness) to receive immediate blood transfusion with 20 ml per kilogram or 30 ml per kilogram. Three other randomized analyses investigated immediate as compared with no immediate transfusion, the administration of postdischarge micronutrients, and postdischarge prophylaxis with trimethoprim-sulfamethoxazole. The primary outcome was 28-day mortality.
RESULTS
A total of 3196 eligible children (median age, 37 months; 2050 [64.1%] with malaria) were assigned to receive a transfusion of 30 ml per kilogram (1598 children) or 20 ml per kilogram (1598 children) and were followed for 180 days. A total of 1592 children (99.6%) in the higher-volume group and 1596 (99.9%) in the lower-volume group started transfusion (median, 1.2 hours after randomization). The mean (±SD) volume of total blood transfused per child was 475±385 ml and 353±348 ml, respectively; 197 children (12.3%) and 300 children (18.8%) in the respective groups received additional transfusions. Overall, 55 children (3.4%) in the higher-volume group and 72 (4.5%) in the lower-volume group died before 28 days (hazard ratio, 0.76; 95% confidence interval [CI], 0.54 to 1.08; P = 0.12 by log-rank test). This finding masked significant heterogeneity in 28-day mortality according to the presence or absence of fever (>37.5°C) at screening (P=0.001 after Sidak correction). Among the 1943 children (60.8%) without fever, mortality was lower with a transfusion volume of 30 ml per kilogram than with a volume of 20 ml per kilogram (hazard ratio, 0.43; 95% CI, 0.27 to 0.69). Among the 1253 children (39.2%) with fever, mortality was higher with 30 ml per kilogram than with 20 ml per kilogram (hazard ratio, 1.91; 95% CI, 1.04 to 3.49). There was no evidence of differences between the randomized groups in readmissions, serious adverse events, or hemoglobin recovery at 180 days.
CONCLUSIONS
Overall mortality did not differ between the two transfusion strategies. (Funded by the Medical Research Council and Department for International Development, United Kingdom; TRACT Current Controlled Trials number, ISRCTN84086586.).
Identifiants
pubmed: 31365800
doi: 10.1056/NEJMoa1900100
pmc: PMC7610610
mid: EMS118816
doi:
Substances chimiques
Hemoglobins
0
Banques de données
ISRCTN
['ISRCTN84086586']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
420-431Subventions
Organisme : Wellcome Trust
ID : 202800
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202800/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12023/26
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_MR/R019258/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U122886353
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12023/17
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J012483/1
Pays : United Kingdom
Organisme : University Hospital Southampton NHS Foundation Trust
ID : MR/JO12485
Pays : International
Investigateurs
S Kiguli
(S)
R O Opoka
(RO)
E Nabawanuka
(E)
J Kayaga
(J)
C Williams Musika
(C)
E Kadama
(E)
I Mbwali
(I)
L Nuwabaine
(L)
R Nakikwaku
(R)
J Nsubuga
(J)
K Mpande
(K)
R Adoo
(R)
O Ouma
(O)
N K Adia
(NK)
P Olupot-Olupot
(P)
J Nteziyaremye
(J)
C Namanyanja
(C)
G Passi
(G)
T Sennyondo
(T)
R Adong
(R)
C B Okalebo
(CB)
E Atimango
(E)
S Mwamula
(S)
J Kapsindet
(J)
G Kiluli
(G)
R Muhindo
(R)
G Masifa
(G)
N Thembo
(N)
G Odong
(G)
C Engoru
(C)
F Alaroker
(F)
M Nakuya
(M)
D Aromut
(D)
M Ariima
(M)
M Itipe
(M)
M G Atim
(MG)
M Abeno
(M)
B Amede
(B)
M Olupot
(M)
S Okwi
(S)
M G Kulume
(MG)
G Among
(G)
P Onyas
(P)
E D Achipa
(ED)
K Maitland
(K)
A Mpoya
(A)
P Maitha
(P)
S Uyoga
(S)
T N Williams
(TN)
A Macharia
(A)
M Mallewa
(M)
Y Chimalizeni
(Y)
N Kennedy
(N)
F Kumwenda
(F)
G Chagaluka
(G)
E Nkosi
(E)
T Sochera
(T)
A Malenga
(A)
B Gushu
(B)
T Phiri
(T)
A Chisale
(A)
N Mitole
(N)
E Chokani
(E)
A Munthali
(A)
D Kyeyune Byabazaire
(D)
B Wabwire
(B)
B M'baya
(B)
G Frost
(G)
K Walsh
(K)
D M Gibb
(DM)
E C George
(EC)
M Thomason
(M)
D Baptiste
(D)
L McCabe
(L)
A S Walker
(AS)
A Ali
(A)
K Khamis
(K)
M Madula
(M)
G Abongo
(G)
P Saramago Goncalves
(P)
P Revill
(P)
S Walker
(S)
A Fox
(A)
R Heydermann
(R)
I Bates
(I)
B Urban
(B)
M Boele von Hensbroek
(M)
F Kyomuhendo
(F)
S Nakalanzi
(S)
J Chabuka
(J)
N Mkandawire
(N)
J Evans
(J)
F Fitzgerald
(F)
E Molyneux
(E)
I Lubega
(I)
M Murphy
(M)
P Kazembe
(P)
J Crawley
(J)
T Peto
(T)
P Musoke
(P)
J Todd
(J)
G Mirembe
(G)
F Tenu
(F)
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2019 Massachusetts Medical Society.
Références
BMC Med. 2015 Feb 02;13:21
pubmed: 25640706
Trials. 2015 Dec 29;16:593
pubmed: 26715196
Malar J. 2010 Oct 30;9:307
pubmed: 21034494
PLoS Med. 2012;9(9):e1001309
pubmed: 22984355
N Engl J Med. 2019 Aug 1;381(5):407-419
pubmed: 31365799
BMC Med. 2014 Apr 25;12:67
pubmed: 24767094
BMJ. 2012 Mar 15;344:e1553
pubmed: 22422832
Vox Sang. 2019 May;114(4):340-348
pubmed: 30838664
Value Health. 2016 Dec;19(8):929-935
pubmed: 27987642
J Clin Pathol. 2005 Jan;58(1):56-60
pubmed: 15623483
Arch Dis Child. 2005 Jul;90(7):724-8
pubmed: 15970617
Lancet Glob Health. 2013 Jul;1(1):e16-25
pubmed: 25103581
PLoS One. 2008 Aug 06;3(8):e2903
pubmed: 18682797
Wellcome Open Res. 2018 Oct 4;3:130
pubmed: 30854471
Clin Infect Dis. 2017 Apr 1;64(7):939-946
pubmed: 28362936
Pediatr Crit Care Med. 2018 Sep;19(9S Suppl 1):S98-S113
pubmed: 30161064
N Engl J Med. 2008 Feb 28;358(9):888-99
pubmed: 18305266
Clin Lab Med. 1996 Dec;16(4):895-906
pubmed: 8974201
Trials. 2011 Mar 31;12:90
pubmed: 21453454
BJOG. 2008 Oct;115(11):1331-9
pubmed: 18823485